Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Arcturus' self-amplifying mRNA (SAM-RNA) technology represents a potential game-changer in the field of mRNA therapeutics and vaccines. This technology allows for longer antigen production from ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism (35% comfortable with technology) and challenges translating ...

Arcturus is advancing its vaccine and rare disease pipeline with significant developments. The initiation of a BARDA-funded Phase 1 study for bird flu, along with ongoing studies in cystic ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics ARCT in the last three months. The table below summarizes their recent ...

HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Cantor Fitzgerald reiterated an ...

"We are pleased with the approval of domestic manufacturing sites in Japan for KOSTAIVE ®," said Dr. Pad Chivukula, COO of Arcturus Therapeutics. "As a joint venture partner with ARCALIS ...

SAN DIEGO, February 04, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious ...

I've been managing this hub of all the latest (and upcoming) Xbox Game Pass additions and departures for years at this point, making this the only source you keep up to date with the newest Game ...

There are so many exciting upcoming PC games on the way in 2025. From sprawling, highly anticipated RPGs to third-person shooters and story-driven experiences, we've brought together the biggest ...